53 results about "Levosimendan" patented technology

A freze-dried Zuoximengdan for treating heart failure is prepared from the pharmacologically acceptable pH regulator and water-soluble precipient, and the solution of Zuoximengdan or its pharmacologically acceptable salt through freeze drying. Its advantage is high stability.

The present invention relates to one kind of heart failure resisting medicine, cyclodextrin or its derivative included preparation of levosimendan. The preparation has calcium-sensitive positive muscle medicine levosimendan as main component, and beta-cyclodextrin or its derivative, such as hydroxypropyl beta-cyclodextrin as including matter.

The invention relates to a stable levosimendan medicine composition. The medicine composition consists of two chambers, wherein a medicine chamber is filled with the levosimendan or a pharmaceutically acceptable salt thereof; and a solvent chamber is filled with a pharmaceutically usable solvent. The solvent contains a pharmaceutically acceptable organic solvent and solubilizing agent, and also can be added with a pharmaceutically acceptable acid. The composition can be used for intravenous injection, or taken orally. The invention also relates to a method for preparing the composition.

A combination therapy for the treatment of acute myocardial infarction comprises administering a combination of a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof to a patient. The combination synergistically reduces mortality of patients with acute myocardial infarction.

The present invention relates to the processing method of 6-(4-amino phenyl)-4, 5-dihydro-5-methyl-3-(2H)-pyridazinone as the intermediate material for levosimendan and pimobendan as cardiac and cerebral vascular diseases medicine. The processing includes the first mixing of 6-(4-amino phenyl)-4, 5-dihydro-5-methyl-3-(2H)-pyridazinone dextroisomer with alkali or acid in 50 %, dissolving with solvent and reflux, evaporation to dry, water washing, and drying to obtain product. The said method can raise material utilization rate and lower product cost, and through four times one racemization and five times of resolution, the accumulated yield may reach 30-40 %, with the single time resolution yield being 8-12 %.

The invention discloses a pharmaceutical solution which takes levosimendan or medicine salt thereof as an active ingredient, takes absolute ethyl alcohol as a solvent, and also comprises maleic acid and solubilizer polyvidone. The pH valve of the pharmaceutical solution ranges from 3 to 4; wherein, the weight-to-volume ratio of the levosimendan or the medicine salt thereof is 0.2 to 0.3 percent, and 0.25 percent is optimized; the weight-to-volume ratio of the maleic acid is 0.001 to 0.01 percent, and the range from 0.005 to 0.009 percent is optimized; the weight-to-volume ratio of the polyvidone is 0.5 to 2 percent, and 1 percent is optimized. A stability experiment shows that pharmaceutical solution has better stability.

The present invention relates to improved formulations of Levosimendan for pharmaceutical use, and particularly for intravenous administration as infusion or injection and of infusion concentrates. The present invention therefore relates to pharmaceutical compositions comprising Levosimendan, in which Levosimendan ispresent in a solubilized form. The formulations have therapeuticallyand commercial useful concentrations of Levosimendan. The solutions of the invention have enhanced ability at physiological pH (pH 7.4) and are particular useful as infusion or injection solutions or infusion concentrates. The composition according to the present invention can also be spray-dried or lyophilized to obtain a dried powder which is very stable and which powder forms the original solutionafter reconstitution in wateror an aqueous solvent. Levosimendan or (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazi-nyl)phenyl]hydrazono]propanedinitrile is useful in the treatment of congestive heart failure.

Methods for treating mammals before, during and after cardiac arrest are disclosed. Pharmaceutical compositions comprising levosimendan useful for such treatment also are disclosed.

A combination therapy for the treatment of heart failure, particularly acute heart failure, comprises administering a combination of levosimendan or a pharmaceutically acceptable salt thereof and a calcium ion source and/or an intracellular calcium increasing agent to a patient. The combination shows a synergistic effect even at doses having no effect if administered alone.

The invention relates to a medicine composition containing levosimendan or the pharmaceutically acceptable salts thereof as active ingredients. The composition comprises the following ingredients: (1) 5-50mg of levosimendan or the pharmaceutically acceptable salts per dose; (2) 10-500mg of povidone K17 per dose; (3) 0.1-100ml of medicinal solvent per dose.

The invention provides a pyridazinone derivative and a synthetic method thereof. The method comprises the steps of: (a) synthesizing 4-carbonyl-4(4-pyridine) butyronityile; (b) synthesizing 4,5-2H-6-(4-pyridine)-3(2H)-pyridazinone; (c) preparing N-ethoxycarbonyl methyl-4-(4,5-pyridazine-3(2H)-ketone-6-yl) pyridine bromide; (d) preparing the target object 4,5-2H-6-((1-ethoxycarbonyl methyl)-1,2,5,6-tetrahydropyridine-4-yl)-3(2H)-pyridazinone. The derivative provided in the invention has an obvious positive inotropic action like levosimendan, therefore, the derivative can be used to research and develop new medicaments treating cardiac insufficiency.

Levosimendan or its active metabolite (II), which have been previously suggested for the treatment of congestive heart failure, are useful in the treatment of renal failure.

Methods of (i) reducing morbidity and/or mortality in a human patient undergoing cardiac surgery; (ii) preventing, or reducing the risk of development of, LCOS in a human patient undergoing cardiac surgery; or (iii) reducing the risk of, intensity of, or occurrence of, one or more postoperative adverse events in a human patient undergoing cardiac surgery. The methods can involve (a) a first period of administering to the patient levosimendan for about 1 hour, in which the administration of levosimendan during the first period is initiated: (i) before skin incision for the cardiac surgery, and (ii) at an infusion dose of about 0.2 μg/kg/min; and (b) a second period of administering to the patient levosimendan for about 23 hours, in which the administration of levosimendan during the second period is initiated at an infusion dose of about 0.1 μg/kg/min.

The invention relates to a levosimendan emulsion or a levosimendan salt emulsion for intravenous injection and a preparation method thereof. The invention is a stable levosimendan oil-in-water emulsion which comprises the active components such as levosimendan or levosimenda salt, oil for injection, emulsifier and water for injection. The emulsion alleviates the irritation to blood vessels while ethanol is taken as solvent, reduces the adverse reaction, improves stability of the emulsion, ensures the safety in the clinical application of the emulsion, and enhances the compliance of patients with the emulsion.

A combination of a levosimendan compound or a pharmaceutically acceptable salt thereof and an angiotensin II receptor antagonist or an angiotensin converting enzyme (ACE) inhibitor shows synergistic effect in the prevention of stroke. Pharmaceutical compositions and medical kits comprising as a first active ingredient a levosimendan compound or a pharmaceutically acceptable salt thereof and as a second active ingredient an angiotensin II receptor antagonist or an angiotensin converting enzyme (ACE) inhibitor are provided.

The invention provides a compound of an angiotensin receptor blocker and levosimendan and use of the compound. The compound is composed of the angiotensin receptor blocker and levosimendan, which can be mixed directly or be connected indirectly through a hydrogen bond, wherein a co-crystallized sodium hydrate formed by connection through hydrogen bond is more stable in property; and the pharmacokinetic properties are improved significantly; the action mechanisms of the angiotensin receptor blocker and the levosimendan are different, but the formed compound has an unexpected synergistic effect and has positive application prospects in the anti-heart failure and anti-hypertensive treatment field.